|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Adenosine#Adult Indications and Dosage]] |
| {{Adenosine}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Dosage and Administration==
| |
| For rapid bolus intravenous use only.
| |
| | |
| '''Adenocard (adenosine injection) should be given as a rapid bolus by the peripheral intravenous route. To be certain the solution reaches the systemic circulation, it should be administered either directly into a vein or, if given into an IV line, it should be given as close to the patient as possible and followed by a rapid saline flush'''.
| |
| | |
| ===Adult Patients===
| |
| The dose recommendation is based on clinical studies with peripheral venous bolus dosing. Central venous (CVP or other) administration of Adenocard has not been systematically studied.
| |
| The recommended intravenous doses for adults are as follows:
| |
| | |
| '''Initial dose''': 6 mg given as a rapid intravenous bolus (administered over a 1-2 second period).
| |
| | |
| '''Repeat administration''': If the first dose does not result in elimination of the [[supraventricular tachycardia]] within 1-2 minutes, 12 mg should be given as a rapid intravenous bolus. This 12 mg dose may be repeated a second time if required.
| |
| | |
| ===Pediatric Patients===
| |
| The dosages used in neonates, infants, children and adolescents were equivalent to those administered to adults on a weight basis.
| |
| Pediatric Patients with a Body Weight < 50 kg:
| |
| | |
| '''Initial dose''': Give 0.05 to 0.1 mg/kg as a rapid IV bolus given either centrally or peripherally. A saline flush should follow.
| |
| | |
| '''Repeat administration''': If conversion of PSVT does not occur within 1-2 minutes, additional bolus injections of adenosine can be administered at incrementally higher doses, increasing the amount given by 0.05 to 0.1 mg/kg. Follow each bolus with a saline flush. This process should continue until sinus rhythm is established or a maximum single dose of 0.3 mg/kg is used.
| |
| Pediatric Patients with a Body Weight ≥ 50 kg: Administer the adult dose.
| |
|
| |
| '''Doses greater than 12 mg are not recommended for adult and pediatric patients.'''
| |
| | |
| '''NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.'''<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |
| [[Category:Antiarrhythmic agents]]
| |